SAN DIEGO, CA – November 21, 2014 – GLYSENS INCORPORATED announced today that it has been awarded a two-year, two million dollar grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). The grant is intended to support human clinical evaluation of the GlySens second generation ICGM™ long term implantable glucose monitoring system. Final preparations for launch of the trial are underway, and enrollment is expected to begin before the end of 2014.
“We are extremely pleased and grateful to have the support of NIDDK and the NIH as we take these next steps in the development of the GlySens ICGM system,” said Joseph Lucisano, PhD, GlySens President and CEO. “As appreciation continues to grow for the potential of continuous glucose monitoring to make a real difference in the lives of people with diabetes, the need to provide an effective, widely acceptable, patient-friendly product has never been greater. We believe that our long term system approach, with its fully implantable sensor intended to operate continuously for one year without need for replacement, will provide the convenience and ease of use that patients desire and foster widespread application of continuous glucose monitoring in diabetes care. The long-standing engagement of the NIH with our research program has provided tremendous value in helping us ensure that our approach aims to serve a broad range of patient needs while we also maintain the highest level of scientific rigor in our efforts. As with our other previous NIH sponsored projects, including the completed human clinical evaluation of the first generation ICGM system, we look forward to conducting this upcoming clinical trial with NIH support.”
About GlySens Incorporated
GlySens Incorporated is a privately held corporation devoted to developing the world’s first truly long term continuous glucose monitoring system, intended to dramatically improve the lives of people with diabetes. The GlySens fully implanted sensor—demonstrated up to 18-month lifetime in preclinical testing—wirelessly links to a convenient external receiver, designed to provide continuous, at-a-glance glucose measurement, recording, and alerts regarding hypo- and hyperglycemic glucose excursions. In contrast with other approaches that may require calibration multiple-times-per-day, system calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from the need for burdensome care and maintenance. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGM™ system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms. Additional information is available at www.glysens.com.
ICGM is a trademark of GlySens Incorporated.
Caution – INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
Research reported in this release was supported by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under grant number R44DK077254. The content of this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.